Figure 7. Knockdown of GPR101 reverses the antiarthritic actions of RvD5_{n-3 DPA}.

Mice were administered 9 μg siRNA targeting mouse Gpr101 or a scrambled control sequence. After 24 hours and 72 hours, mice were administered arthritogenic serum and then treated with RvD5_{n-3 DPA} (150 ng/mouse) or vehicle (72 hours and 96 hours after siRNA administration). (A) Clinical scores, (B) AUC for clinical scores, (C) weight loss, and (D) edema were determined throughout the disease process. (E and F) On day 7, hind paws were harvested and eicosanoid concentrations determined using LC-MS/MS–based lipid mediator profiling. (E) Prostaglandin and (F) LTB₄ metabolomic concentrations. Results represent the mean ± SEM (n = 4 mice per group). *P < 0.05 versus the vehicle-treated group; Kruskal-Wallis test with Dunn’s post hoc multiple comparisons test (B, E, and F) and 2-way ANOVA (C and D).